SLN Silence Therapeutics
- 23.360
- +0.420+1.83%
Silence Therapeutics News
European Equities Traded in the US as American Depositary Receipts Trend Modestly Higher in Friday Trading
European equities traded in the US as American depositary receipts were trending modestly higher late Friday morning, rising 0.29% to 1,426.43 on the S&P Europe Select ADR Index. The index is set to c
Chardan Capital: Maintains Silence Therapeutics (SLN.US) rating, adjusted from buy to buy rating, and adjusted target price from $42.00 to $42.00.
Chardan Capital: Maintains Silence Therapeutics (SLN.US) rating, adjusted from buy to buy rating, and adjusted target price from $42.00 to $42.00.
Chardan Capital Maintains Buy on Silence Therapeutics, Maintains $42 Price Target
Chardan Capital analyst Keay Nakae maintains Silence Therapeutics with a Buy and maintains $42 price target.
Silence Therapeutics (SLN.US): The 2024 Q1 financial report achieved revenue of US$15.734 million, previous value of US$13.815 million; earnings per share were -0.05 USD, prior value of -0.12 USD.
Silence Therapeutics (SLN.US): The 2024 Q1 financial report achieved revenue of US$15.734 million, previous value of US$13.815 million; earnings per share were -0.05 USD, prior value of -0.12 USD.
Silence Therapeutics Posts Reduced Q1 Losses
6-K: Report of foreign private issuer (related to financial reporting)
European Equities Traded in the US as American Depositary Receipts Trend Lower in Thursday Trading
European equities traded in the US as American depositary receipts were trending moderately lower late Thursday morning, declining 0.61% to 1,426.72 on the S&P Europe Select ADR Index. From continenta
Silence Therapeutics Q1 Collaboration Revenue £12.4M, Up £1M YoY; Cash Position £152.8M
Silence Therapeutics Q1 Collaboration Revenue £12.4M, Up £1M YoY; Cash Position £152.8M
Silence Therapeutics 1Q Rev GBP12.4M >SLN
Silence Therapeutics 1Q Rev GBP12.4M >SLN
Press Release: Silence Therapeutics Reports First Quarter 2024 Results and Highlights Pipeline Progress
Silence Therapeutics Reports First Quarter 2024 Results and Highlights Pipeline Progress LONDON--(BUSINESS WIRE)--May 16, 2024-- Silence Therapeutics plc, Nasdaq: SLN ("Silence" or "the Company"), a
European Equities Traded in the US as American Depositary Receipts Nudge Higher in Wednesday Trading
European equities traded in the US as American depositary receipts were trending slightly higher Wednesday morning, rising 0.10% to 1,427.23 on the S&P Europe Select ADR Index. From continental Europe
European Equities Traded in the US as American Depositary Receipts Kick Off Week Higher
European equities traded in the US as American depositary receipts kicked off the week higher in Monday morning, rising 0.62% to 1,421.16 on the S&P Europe Select ADR Index. From continental Europe, t
European Equities Traded in the US as American Depositary Receipts Rise in Thursday Trading
European equities traded in the US as American depositary receipts rose late Thursday morning, gaining 0.35% to 1,403.4 on the S&P Europe Select ADR Index. From continental Europe, the gainers were le
Silence Therapeutics Files to Sell 5.71M American Depositary Shares for Holders
Silence Therapeutics Announces Board Change
Silence Therapeutics to Participate in Fireside Chat at H.C. Wainwright 2nd Annual BioConnect Investor Conference
Silence Therapeutics plc, Nasdaq: SLN ("Silence" or the "Company"), an experienced and innovative biotechnology company committed to transforming people's lives by silencing diseases through precision engineered
Silence Therapeutics Announces Retirement of Alistair Gray From Board of Directors
Silence Therapeutics plc (NASDAQ:SLN) ("Silence" or the "Company"), an experienced and innovative biotechnology company committed to transforming people's lives by silencing diseases through precision engineered
Beyond The Numbers: 7 Analysts Discuss Silence Therapeutics Stock
7 analysts have expressed a variety of opinions on Silence Therapeutics (NASDAQ:SLN) over the past quarter, offering a diverse set of opinions from bullish to bearish.The table below summarizes their
Silence Therapeutics Is Maintained at Overweight by Morgan Stanley
Silence Therapeutics Is Maintained at Overweight by Morgan Stanley
Damo: Maintaining the Silence Therapeutics (SLN.US) rating, adjusted from an increase holdings to an increase rating, and the target price was adjusted from $45.00 to $45.00.
Damo: Maintaining the Silence Therapeutics (SLN.US) rating, adjusted from an increase holdings to an increase rating, and the target price was adjusted from $45.00 to $45.00.
Analysis
Price Target
No Data
